title: Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer.
abstract: This phase II study assessed the clinical efficacy and tolerability of a combination of mitomycin C, vinblastine and cisplatin in patients with metastatic breast cancer (MBC) previously treated with chemotherapy. A total of 87 patients with MBC, most of whom had been exposed to anthracyclines (92%) and/or taxanes (29%) in the adjuvant and/or metastatic setting, were treated with mitomycin C (8 mg m(-2) day 1 cycles 1, 2, 4 and 6), vinblastine (6 mg m(-2) day 1) and cisplatin (50 mg m(-2) day 1) repeated each 21 days for a maximum of six cycles. The overall response rate (ORR) was 32% (95% CI: 22-42%) with 31% partial response (PR) and one complete response (CR). Stable disease (SD) rate was 21% (95% CI: 12-29%). There was no statistically significant difference in the ORR when MVP was given as the first-line treatment for MBC vs second or subsequent line (38 vs 30%, P=0.6), or between patients with an early (<6 months) vs late (>6 months) relapse post-anthracyclines (30 vs 52%, P=0.3). Toxicity profile was mild. This platinum-based chemotherapy is an effective, well-tolerated and low-cost regimen for patients with MBC, including those pretreated with anthracyclines.
authors.affiliation: Department of Medicine--Breast Unit, Royal Marsden NHS Trust, London and Surrey, England.
authors.forename: A
authors.initials: A
authors.lastname: Urruticoechea
authors.forename: C D
authors.initials: CD
authors.lastname: Archer
authors.forename: L A
authors.initials: LA
authors.lastname: Assersohn
authors.forename: R K
authors.initials: RK
authors.lastname: Gregory
authors.forename: M
authors.initials: M
authors.lastname: Verrill
authors.forename: R
authors.initials: R
authors.lastname: Mendes
authors.forename: G
authors.initials: G
authors.lastname: Walsh
authors.forename: I E
authors.initials: IE
authors.lastname: Smith
authors.forename: S R D
authors.initials: SR
authors.lastname: Johnston
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D016879:Salvage Therapy; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D016685:Mitomycin; D014747:Vinblastine; D002945:Cisplatin